دورية أكاديمية
أعرض في EDS

Macrolide resistance among Streptococcus agalactiae during COVID-19 public health emergency in Brazil.

التفاصيل البيبلوغرافية
العنوان: Macrolide resistance among Streptococcus agalactiae during COVID-19 public health emergency in Brazil.
المؤلفون: Barros RR; Departamento de Microbiologia e Parasitologia, Instituto Biomédico, Universidade Federal Fluminense, Rua Hernani de Melo 101 sala 304, 24210-130, Niterói, RJ, Brazil. rrbarros@id.uff.br., Barros CC; Departamento de Microbiologia e Parasitologia, Instituto Biomédico, Universidade Federal Fluminense, Rua Hernani de Melo 101 sala 304, 24210-130, Niterói, RJ, Brazil., Kegele FCO; Instituto Fernandes Figueira, Fundação Oswaldo Cruz, Av. Rui Barbosa 716, 22250-020, Rio de Janeiro, RJ, Brazil., Francisca da S N Soares M; Instituto Fernandes Figueira, Fundação Oswaldo Cruz, Av. Rui Barbosa 716, 22250-020, Rio de Janeiro, RJ, Brazil., de Paula GR; Faculdade de Farmácia, Universidade Federal Fluminense, Rua Dr. Mário Viana 523, 24241-000, Niterói, RJ, Brazil.
المصدر: Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] [Braz J Microbiol] 2024 Jun; Vol. 55 (2), pp. 1445-1449. Date of Electronic Publication: 2024 Apr 30.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Springer International Publishing Country of Publication: Brazil NLM ID: 101095924 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1678-4405 (Electronic) Linking ISSN: 15178382 NLM ISO Abbreviation: Braz J Microbiol Subsets: MEDLINE
أسماء مطبوعة: Publication: 2019- : Switzerland, AG : Springer International Publishing
Original Publication: Rio de Janeiro, RJ, Brasil : Sociedade Brasileira de Microbiologia
مواضيع طبية MeSH: Streptococcus agalactiae*/drug effects , Streptococcus agalactiae*/genetics , Streptococcus agalactiae*/isolation & purification , Streptococcus agalactiae*/classification , Anti-Bacterial Agents*/pharmacology , Streptococcal Infections*/microbiology , Streptococcal Infections*/epidemiology , COVID-19*/epidemiology , Microbial Sensitivity Tests* , Drug Resistance, Bacterial* , SARS-CoV-2*/drug effects , SARS-CoV-2*/genetics , Macrolides*/pharmacology, Humans ; Brazil/epidemiology ; Pregnancy ; Female ; Clindamycin/pharmacology ; Erythromycin/pharmacology ; Public Health
مستخلص: During COVID-19 public health emergence, azithromycin was excessively used in Brazil, as part of a controversial "early treatment", recommended by former national health authorities. Excessive usage of macrolides may increase resistance rates among beta-hemolytic streptococci. Therefore, this study aimed to investigate the occurrence of resistance to erythromycin and clindamycin among Streptococcus agalactiae recovered from February 2020 to May 2023. Bacterial isolates (n = 116) were obtained from pregnant women and submitted to antimicrobial susceptibility testing, investigation of macrolide resistance phenotypes and genotypes, and identification of capsular type. The overall rate of erythromycin not susceptible (NS) isolates was 25.9%, while resistance to clindamycin was 5.2%. Drug efflux, associated with the M phenotype and mef(A) gene, was the prevalent mechanism of resistance (80%). Capsular type Ia was predominant (39.8%), followed by II, III, and V (17.7% each). A higher diversity of types was observed in the last years of the study. Type IV has had an increasing trend over time, being the fourth most common in 2023. The majority of the isolates that expressed the M phenotype presented capsular type Ia, while those with iMLS phenotype presented capsular type V. Despite no causal relationship can be established, azithromycin excessive usage may be a possible factor associated with this higher rate of erythromycin NS isolates, compared with most previous national studies. On the other hand, resistance to clindamycin has not changed significantly. Therefore, in the studied clinical setting, clindamycin remains a useful alternative to intrapartum prophylaxis among penicillin-allergic pregnant women.
(© 2024. The Author(s) under exclusive licence to Sociedade Brasileira de Microbiologia.)
References: Microbiol Spectr. 2018 Mar;6(2):. (PMID: 29600772)
J Antimicrob Chemother. 2016 Jul;71(7):2054-6. (PMID: 27029847)
J Clin Microbiol. 2007 Jun;45(6):1985-8. (PMID: 17376884)
Antimicrob Agents Chemother. 2007 Apr;51(4):1228-33. (PMID: 17242142)
Rev Inst Med Trop Sao Paulo. 2016 Nov 03;58:83. (PMID: 27828624)
Antimicrob Agents Chemother. 2009 Jun;53(6):2650-3. (PMID: 19332682)
Obstet Gynecol. 2020 Feb;135(2):e51-e72. (PMID: 31977795)
Microorganisms. 2022 Nov 23;10(12):. (PMID: 36557569)
Euro Surveill. 2014 Jun 12;19(23):. (PMID: 24957747)
PLoS One. 2018 May 11;13(5):e0196925. (PMID: 29750801)
Front Immunol. 2014 Oct 29;5:519. (PMID: 25400631)
Pathogens. 2022 Sep 27;11(10):. (PMID: 36297161)
World J Clin Cases. 2020 Sep 26;8(18):3988-3998. (PMID: 33024755)
J Infect Prev. 2021 May;22(3):119-125. (PMID: 34239610)
N Engl J Med. 1997 Aug 14;337(7):441-6. (PMID: 9250845)
Antimicrob Agents Chemother. 1996 Aug;40(8):1817-24. (PMID: 8843287)
معلومات مُعتمدة: APQ1 211.681 Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro
فهرسة مساهمة: Keywords: Streptococcus agalactiae; Microbial drug resistance; Pregnant women
المشرفين على المادة: 0 (Anti-Bacterial Agents)
0 (Macrolides)
3U02EL437C (Clindamycin)
63937KV33D (Erythromycin)
تواريخ الأحداث: Date Created: 20240430 Date Completed: 20240605 Latest Revision: 20240608
رمز التحديث: 20240608
مُعرف محوري في PubMed: PMC11153377
DOI: 10.1007/s42770-024-01356-4
PMID: 38687418
قاعدة البيانات: MEDLINE
الوصف
تدمد:1678-4405
DOI:10.1007/s42770-024-01356-4